German generic drugs company Stada said on Thursday it had received its third takeover approach, and at 58 euros ($61.89) per share, the latest offer was two euros higher than rival suitor Cinven Partners’ offer.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
